Home/Filings/4/0000899243-20-034365
4//SEC Filing

Versant Vantage I GP-GP, LLC 4

Accession 0000899243-20-034365

CIK 0001808158other

Filed

Dec 16, 7:00 PM ET

Accepted

Dec 17, 9:05 PM ET

Size

20.4 KB

Accession

0000899243-20-034365

Insider Transaction Report

Form 4
Period: 2020-12-15
Transactions
  • Other

    Common Shares

    2020-12-158,57976,158 total(indirect: See Footnote)
  • Other

    Common Shares

    2020-12-15285,2172,531,804 total(indirect: See Footnote)
  • Other

    Common Shares

    2020-12-1521,707192,683 total(indirect: See Footnote)
  • Other

    Common Shares

    2020-12-159,49784,301 total(indirect: See Footnote)
Holdings
  • Common Shares

    (indirect: See Footnote)
    3,419,451
  • Common Shares

    608,282
Transactions
  • Other

    Common Shares

    2020-12-15285,2172,531,804 total(indirect: See Footnote)
  • Other

    Common Shares

    2020-12-158,57976,158 total(indirect: See Footnote)
  • Other

    Common Shares

    2020-12-159,49784,301 total(indirect: See Footnote)
  • Other

    Common Shares

    2020-12-1521,707192,683 total(indirect: See Footnote)
Holdings
  • Common Shares

    (indirect: See Footnote)
    3,419,451
  • Common Shares

    608,282
Transactions
  • Other

    Common Shares

    2020-12-15285,2172,531,804 total(indirect: See Footnote)
  • Other

    Common Shares

    2020-12-158,57976,158 total(indirect: See Footnote)
  • Other

    Common Shares

    2020-12-159,49784,301 total(indirect: See Footnote)
  • Other

    Common Shares

    2020-12-1521,707192,683 total(indirect: See Footnote)
Holdings
  • Common Shares

    608,282
  • Common Shares

    (indirect: See Footnote)
    3,419,451
Footnotes (10)
  • [F1]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V, L.P. ("VVC V"), to its partners, pursuant to a Rule 10b5-1 trading plan.
  • [F10]Shares held by Versant Vantage I, L.P. ("VV I"). Versant Vantage I GP-GP, LLC ("VV I GP-GP") is the sole general partner of Versant Vantage I GP, L.P. ("VV I GP") and VV I GP is the sole general partner of VV I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV I GP-GP and may be deemed to share voting and dispositive power over the shares held by VV I. Each of VV I GP-GP, VV I GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VV I, except to the extent of their respective pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
  • [F2]Shares held by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VVC V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V, except to the extent of their respective pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
  • [F3]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Affiliates Fund V, L.P. ("VAF V"), to its partners, pursuant to a Rule 10b5-1 trading plan.
  • [F4]Shares held by VAF V. VV V is the sole general partner of VAF V. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VAF V. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VAF V, except to the extent of their respective pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
  • [F5]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Ophthalmic Affiliates, L.P. ("VOAF I"), to its partners, pursuant to a Rule 10b5-1 trading plan.
  • [F6]Shares held by VOAF I. VV V is the sole general partner of VOAF I. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV V and may be deemed to share voting and dispositive power over the shares held by VOAF I. Each of VV V and Jerel C. Davis disclaims beneficial ownership of the shares held by VOAF I, except to the extent of their respective pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
  • [F7]Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by Versant Venture Capital V (Canada) LP ("VVC V (Canada)"), to its partners, pursuant to a Rule 10b5-1 trading plan.
  • [F8]Shares held by VVC V (Canada). Versant Ventures V (Canada) GP-GP, Inc. ("VV V (Canada) GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V (Canada)") and VV V (Canada) is the sole general partner of VVC V (Canada). Jerel C. Davis, a member of the Issuer's board of directors, is a director of VV V (Canada) GP and may be deemed to share voting and dispositive power over the shares held by VVC V (Canada). Each of VV V (Canada), VV V (Canada) GP and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC V (Canada), except to the extent of their respective pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.
  • [F9]Shares held by Versant Venture Capital VI, L.P. ("VVC VI"). Versant Ventures VI GP-GP, LLC ("VV VI GP") is the sole general partner of Versant Ventures VI GP, L.P. ("VV VI") and VV VI is the sole general partner of VVC VI. Jerel C. Davis, a member of the Issuer's board of directors, is a managing member of VV VI GP and may be deemed to share voting and dispositive power over the shares held by VVC VI. Each of VV VI GP, VV VI and Jerel C. Davis disclaims beneficial ownership of the shares held by VVC VI, except to the extent of their respective pecuniary interest therein. Jerel C. Davis is a director of the Issuer and, accordingly files separate Section 16 reports.

Issuer

Repare Therapeutics Inc.

CIK 0001808158

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001777653

Filing Metadata

Form type
4
Filed
Dec 16, 7:00 PM ET
Accepted
Dec 17, 9:05 PM ET
Size
20.4 KB